Searching for 'the Goldilocks zone' – how a biotech VC firm translates difficult decisions into marketable medicines

4 January 2019

Members of the deals team at Arix Bioscience (LSE: ARIX), a London-listed venture capital (VC) firm specializing in biotech, are so well-connected that they will never lack for new innovations to invest in.

But great science doesn’t always translate into commercial opportunities.

And anyone who looks closely will see that bringing the two together is far from easy – the high failure rates at all stages of drug development and the billions that the world’s biggest drug companies lose as a result, the consistent failure of generalist investors to succeed in biotech, and the team’s own academic and real-life experience of science and business are all evidence that this is a highly specialist field.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK